Sumitomo Mitsui Trust Group Inc. Acquires 13,102 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Sumitomo Mitsui Trust Group Inc. boosted its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 11.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 125,097 shares of the medical research company’s stock after buying an additional 13,102 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Charles River Laboratories International were worth $23,093,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in CRL. Versant Capital Management Inc grew its position in shares of Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 150 shares during the period. Wolff Wiese Magana LLC purchased a new position in Charles River Laboratories International during the third quarter valued at $32,000. Pinnacle Bancorp Inc. grew its holdings in Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 65 shares during the period. Assetmark Inc. increased its position in Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after buying an additional 173 shares in the last quarter. Finally, ORG Wealth Partners LLC bought a new position in shares of Charles River Laboratories International in the fourth quarter worth about $56,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Trading Down 3.1 %

Shares of CRL opened at $154.93 on Wednesday. The stock has a market capitalization of $7.92 billion, a PE ratio of 19.39, a P/E/G ratio of 6.47 and a beta of 1.37. The company’s fifty day moving average is $178.90 and its 200 day moving average is $192.24. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. Charles River Laboratories International, Inc. has a fifty-two week low of $154.01 and a fifty-two week high of $275.00.

Analyst Ratings Changes

CRL has been the subject of a number of recent research reports. Evercore ISI boosted their price objective on Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research note on Thursday, November 7th. StockNews.com cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. CLSA cut shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price on the stock. in a research note on Monday, November 18th. JPMorgan Chase & Co. dropped their target price on shares of Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating for the company in a report on Monday, February 3rd. Finally, TD Cowen raised their price target on Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a report on Monday, November 11th. Three investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $200.79.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).